Literature DB >> 28321078

Helicobacter cinaedi Bacteremia Mimicking a Flare of Systemic Lupus Erythematosus.

Ruriko Nishida1, Nobuyuki Shimono, Noriko Miyake, Yong Chong, Shinji Shimoda, Hiroshi Tsukamoto, Koichi Akashi.   

Abstract

A 40-year-old woman with systemic lupus erythematosus (SLE) presented with high-grade fever and severe thrombocytopenia. Acalculous cholecystitis and thrombocytopenia were initially suspected to be complicated with SLE and vasculitis. Contrary to our expectation, however, the patient was finally diagnosed with Helicobacter cinaedi bacteremia. SLE patients show various symptoms, especially when their condition is complicated with vasculitis, which mimics H. cinaedi bacteremia. It is therefore difficult to provide a definite diagnosis. Physicians should be mindful of the presence of H. cinaedi infection.

Entities:  

Mesh:

Year:  2017        PMID: 28321078      PMCID: PMC5410488          DOI: 10.2169/internalmedicine.56.7287

Source DB:  PubMed          Journal:  Intern Med        ISSN: 0918-2918            Impact factor:   1.271


Introduction

Helicobacter cinaedi has come to be recognized as an important organism, especially among immunocompromised patients. H. cinaedi grows slowly and is difficult to isolate in culture. H. cinaedi sometimes causes cellulitis but the main symptom is only fever without any focal findings in most cases. Furthermore, unlike most other infectious diseases, the clinical course is not acute. For these reasons, it is difficult to accurately diagnose. When an SLE patient becomes febrile, we should determine whether there has been an exacerbation of SLE itself or whether the condition is a complication of an infectious disease. This is vital because opposite strategies are used in the treatment of SLE and infectious diseases. In the present case, H. cinaedi bacteremia occurred in a patient with SLE, who initially only showed fever. This was followed by atypical symptoms, including severe thrombocytopenia and acalculous cholecystitis. These symptoms mimicked a flare of the disease, which led us initiate the bolus administration of methylprednisolone.

Case Report

A 40-year-old woman was diagnosed with SLE at 20 years of age. Her symptoms included a typical rash, severe multiple organ failure, consciousness disturbance and retinal vasculitis. A laboratory analysis revealed reduced C3, C4 and CH50 levels (20 mg/dL, 7 mg/dL and 10 U/mL, respectively) and anti-nuclear antibody positivity (640×, homogenous, speckled), and anti-DNA antibody negativity. She was in a severe condition and was refractory to the initial treatment of prednisolone (1 mg/kg/day). Plasmapheresis, high-dose methylprednisolone (1 g bolus for 3 days) and an increased dose of prednisolone (1.3 mg/kg/day) were necessary to achieve remission from SLE. After the initial therapy, her condition remained stable with the administration of prednisolone (10 mg/day) for more than 10 years. A regular blood examination showed a gradual increase in the patient's C-reactive protein (CRP) level from 3 months before her admission, which had previously been normal. At first, an exacerbation of SLE was suspected and the amount of prednisolone was increased to 15 mg/day. One month before the admission, she suffered from a high grade fever (39℃) at night with shivering, chills and mild nausea. She was admitted to our hospital to undergo further examination. Her consciousness was clear, without diarrhea, cellulitis or arthritis. On admission, a complete blood cell count revealed anemia (Hb, 7.3 g/dL) with an increase in the number of fragmented red blood cells, leukocytosis (WBC, 18,880 /μL) with neutrophilia (93.5%), and severe thrombocytopenia (platelet count, 37,000 /μL). The patient's CRP level was elevated (14.95 mg/dL). Tests for anti-nuclear antibodies and anti-DNA antibodies were negative and the patient's complement values were normal (C3, 87 mg/dL, C4, 24 mg/dL, and CH50, 51 U/mL). An interferon-γ release assay TB was negative and no vegetation was observed by transthoracic echocardiography. Computed tomography showed significant thickening of the patient's gallbladder wall (Fig. 1) and the values of alkaline phosphatase and γ-glutamyltranspeptidase were also elevated; however, she had no abdominal pain. After admission, her high fever lasted and her anemia and thrombocytopenia advanced rapidly. The patient's blood cultures being negative, and the focus of infection had not been detected on the fourth day of admission. We were therefore forced to start methylprednisolone (1,000 mg/day) due to suspected acalculous cholecystitis which was thought to have occurred due to a flare of SLE or a complication of vasculitis. The next day, the patient's blood cultures were found to be positive (after 5 days of incubation) and microscopy showed gram-negative spiral bacteria (Fig. 2). The isolate was finally identified as H. cinaedi by a PCR and 16S rRNA gene sequencing. We considered that the patient's thrombocytopenia had been caused by H. cinaedi bacteremia, and stopped the bolus administration of methylprednisolone; prednisolone was reduced to the maintenance dose. With the administration of meropenem, the patient's temperature decreased and there was an improvement in her laboratory data with regard to her platelet count, CRP level, and the number of fragmented red blood cells. The clinical course is shown in Fig. 3. The antibiotic was changed and de-escalated to ampicillin, which caused a systemic drug eruption. Doripenem was administered for 3 weeks; thus, the total duration of treatment reached 5 weeks, at which point, the antibiotics were stopped due to pancytopenia. One month after the treatment, the H. cinaedi bacteremia relapsed with a high-grade fever and cellulitis (Fig. 4). Meropenem was administered intravenously for another 2 weeks, and 6 weeks of oral minocycline were given, no relapse occurred after this treatment.
Figure 1.

Abdominal CT on admission showing the thickness of the gallbladder wall (white arrowheads). There were no gallstones.

Figure 2.

The Gram-negative spiral bacterium in the blood culture (black arrows).

Figure 3.

The clinical course of the present case. PSL: prednisolone, mPSL: methylprednisolone, MEPM: meropenem, ABPC: ampicillin, IPM/CS: imipenem/cilastatin, AZM: azithromycin, DRPM: doripenem, WBC: white blood cell (/μL), Hb: hemoglobin (g/dL), PLT: platelet (×103/μL), AST: aspartate aminotransferase (U/L), ALT: alanine aminotransferase (U/L), ALP: alkaline phosphatase (U/L), CRP: C-reactive protein (mg/dL), closed triangle: positive blood culture, open triangle: negative blood culture

Figure 4.

Cellulitis complicated with secondary bacteremia was seen on both extremities and the patient’s back.

Abdominal CT on admission showing the thickness of the gallbladder wall (white arrowheads). There were no gallstones. The Gram-negative spiral bacterium in the blood culture (black arrows). The clinical course of the present case. PSL: prednisolone, mPSL: methylprednisolone, MEPM: meropenem, ABPC: ampicillin, IPM/CS: imipenem/cilastatin, AZM: azithromycin, DRPM: doripenem, WBC: white blood cell (/μL), Hb: hemoglobin (g/dL), PLT: platelet (×103/μL), AST: aspartate aminotransferase (U/L), ALT: alanine aminotransferase (U/L), ALP: alkaline phosphatase (U/L), CRP: C-reactive protein (mg/dL), closed triangle: positive blood culture, open triangle: negative blood culture Cellulitis complicated with secondary bacteremia was seen on both extremities and the patient’s back.

Discussion

H. cinaedi is a gram-negative spiral bacterium that belongs to the Helicobacteriaceae family. It is hypothesized that H. cinaedi infection occurs via the oral route. In some reports, the possibility of zoonotic transmission from animal feces to humans has been discussed. However, the patient had no pets and no contact with animals. The infection route was unclear in this case. It grew slowly and required a more time to be isolated in blood cultures. The median time for H. cinaedi to become positive in blood cultures is 5 days (2-12 days), and the positive ratios from 5 to 7 days were only 55% and 87%, respectively (1). In order to successfully detect H. cinaedi bacteremia, at least 7 days of incubation should be necessary, although only 1-3 days are sufficient for most other organisms. The other characteristics of H. cinaedi bacteremia are nonspecific symptoms and a tendency of relapse. It has been hypothesized that H. cinaedi infection is associated with cellulitis, arthritis and gastroenteritis (2-4); however, fever is the only symptom in many cases. Actually, in ten cases of H. cinaedi bacteremia that were observed in our hospital in the eight years from 2007 to 2014, the only symptom was fever in five cases. The four cases of ten showed skin lesions; however, these were very mild in all of the cases. It might be a result of the lower virulence of H. cinaedi. The appropriate antimicrobial agents and the duration of the treatment for H. cinaedi infection have not been established. Carbapenems, tetracycline, aminoglycosides and penicillins are generally effective (4). Although we treated the patient for a sufficient length of time (5 weeks), she nevertheless relapsed. H. cinaedi bacteremia cases are usually reported in immunocompromised patients such as those with HIV infection, hematological disorders, malignancies, alcoholism and receiving immunosuppressive therapy (5,6). Some other infectious diseases have been reported to mimic SLE or a flare of SLE, human parvovirus B19, cytomegalovirus, visceral leishmaniasis, which is only in endemic area, and so on (7,8). Some bacterial infections may mimic a flare of SLE, and H. cinaedi might be one of them. However, as far as we are aware, reported cases on H. cinaedi bacteremia with SLE are very rare (9). We finally diagnosed gallbladder thickening and thrombocytopenia, which were associated with H. cinaedi infection itself, not with a flare of SLE. Although the association with hepatobiliary diseases and enterohepatic Helicobacter species have been mentioned, most cases were caused by H. bilis or H. hepaticus (10), and not H. cinaedi or cinaedi, there have been only a few reports on hepatobiliary diseases in animals (11) and only one report on hepatobiliary diseases in humans. Our case might represent a possible presentation of the hepatobiliary infections caused by H. cinaedi in humans. In conclusion, we should be mindful of the presence of H. cinaedi bacteremia, especially when we see febrile immunocompromised patients such as patients with SLE. H. cinaedi takes longer to diagnose, the most popular symptom is only fever and it is sometimes associated with various symptoms. Once an H. cinaedi infection is diagnosed, it is necessary to treat the patient with antibiotics for more than one month due to the tendency to relapse.
  11 in total

1.  Recurrent Helicobacter cinaedi bacteremia in a patient infected with human immunodeficiency virus: case report.

Authors:  M P Mammen; N E Aronson; W J Edenfield; T P Endy
Journal:  Clin Infect Dis       Date:  1995-10       Impact factor: 9.079

Review 2.  Clinical and bacteriological characteristics of Helicobacter cinaedi infection.

Authors:  Yoshiaki Kawamura; Junko Tomida; Yuji Morita; Shigemoto Fujii; Tatsuya Okamoto; Takaaki Akaike
Journal:  J Infect Chemother       Date:  2014-07-09       Impact factor: 2.211

Review 3.  Visceral leishmaniasis mimicking systemic lupus erythematosus: Case series and a systematic literature review.

Authors:  Iuri Usêda Santana; Blenda Dias; Eduardo Araújo Santana Nunes; Francisco Airton Castro da Rocha; Francisco Saraiva Silva; Mittermayer Barreto Santiago
Journal:  Semin Arthritis Rheum       Date:  2014-12-29       Impact factor: 5.532

4.  Isolation of Helicobacter cinaedi from the colon, liver, and mesenteric lymph node of a rhesus monkey with chronic colitis and hepatitis.

Authors:  J G Fox; L Handt; B J Sheppard; S Xu; F E Dewhirst; S Motzel; H Klein
Journal:  J Clin Microbiol       Date:  2001-04       Impact factor: 5.948

Review 5.  Multifocal cellulitis and monoarticular arthritis as manifestations of Helicobacter cinaedi bacteremia.

Authors:  W J Burman; D L Cohn; R R Reves; M L Wilson
Journal:  Clin Infect Dis       Date:  1995-03       Impact factor: 9.079

6.  Clinical characteristics of bacteremia caused by Helicobacter cinaedi and time required for blood cultures to become positive.

Authors:  Hideki Araoka; Masaru Baba; Muneyoshi Kimura; Masahiro Abe; Hiroko Inagawa; Akiko Yoneyama
Journal:  J Clin Microbiol       Date:  2014-02-26       Impact factor: 5.948

7.  Recurrent Helicobacter cinaedi cellulitis and bacteremia in a patient with systemic lupus erythematosus.

Authors:  Hirotoshi Kikuchi; Kurumi Asako; Shigeru Tansho; Takane Ueda; Osamu Koshio; Tuneyuki Ubagai; Miwa Asahara; Sayoko Kawakami; Yasuo Ono
Journal:  Intern Med       Date:  2012-11-15       Impact factor: 1.271

8.  Multicenter study to evaluate bloodstream infection by Helicobacter cinaedi in Japan.

Authors:  Tetsuya Matsumoto; Mieko Goto; Hinako Murakami; Takashi Tanaka; Hiroyuki Nishiyama; Emi Ono; Chikako Okada; Etsuko Sawabe; Michiko Yagoshi; Akiko Yoneyama; Katsuko Okuzumi; Kazuhiro Tateda; Naoaki Misawa; Keizo Yamaguchi
Journal:  J Clin Microbiol       Date:  2007-06-27       Impact factor: 5.948

Review 9.  Acute viral infections in patients with systemic lupus erythematosus: description of 23 cases and review of the literature.

Authors:  Manuel Ramos-Casals; María José Cuadrado; Paula Alba; Giovanni Sanna; Pilar Brito-Zerón; Laura Bertolaccini; Alejandra Babini; Asunción Moreno; David D'Cruz; Munther A Khamashta
Journal:  Medicine (Baltimore)       Date:  2008-11       Impact factor: 1.889

Review 10.  Enterohepatic Helicobacter other than Helicobacter pylori.

Authors:  Beatriz Mateos-Muñoz; Julio Pérez-de-la-Serna; Antonio Ruiz-de-León; Blanca Serrano-Falcón; Sergio Casabona-Francés; Aurelio Velasco-Cerrudo; Enrique Rey-Díaz-Rubio
Journal:  Rev Esp Enferm Dig       Date:  2013-09       Impact factor: 2.086

View more
  1 in total

1.  Hellenic consensus on Helicobacter pylori infection.

Authors:  Sotirios D Georgopoulos; Spyridon Michopoulos; Theodoros Rokkas; Pericles Apostolopoulos; Evangelos Giamarellos; Dimitrios Kamberoglou; Andreas Mentis; Konstantinos Triantafyllou
Journal:  Ann Gastroenterol       Date:  2020-01-07
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.